Gossamer Bio and Chiesi Group have announced a a global collaboration agreement to develop seralutinib, an inhaled investigational drug for the treatment of pulmonary arterial hypertension. Seralutinib is currently being investigated in the ongoing global Phase 3 trial, PROSERA, for pulmonary arterial hypertension.
This collaboration further enhances the resources and expertise devoted to seralutinib and facilitates the clinical development of seralutinib in additional pulmonary hypertension indications of high unmet need, including pulmonary hypertension with interstitial lung disease PH-ILD. The plan is to initiate a global Phase 3 clinical trial for the treatment of patients with PH-ILD in 2025. Both Gossamer and Chiesi are committed to advancing seralutinib and believe strongly in its potential to address the significant unmet need within pulmonary hypertension.
Read more at this link on the Gossamer Bio website
